Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Israel / NCT05882175
Recruiting Observational

Prospective Validation of the OHI Index

NCT05882175 · tracked via the Priya Life Science Israel tracker
Sponsor
Meir Medical Center
Phase
Observational
Started
2021-03-03
Last updated
2025-05-13

Condition(s) studied

HLHHemophagocytic LymphohistiocytosesHemophagocytic SyndromeHematologic MalignancyHematologic Neoplasms

Study summary

Hemophagocytic lymphohistiocytosis (HLH) associated with hematologic malignancies (HM-HLH) is a syndrome with an abysmal prognosis (10-30% 5 years overall survival). The investigators have recently established an improved diagnostic and prognostic index for HM-HLH, termed the Optimized HLH Inflammatory (OHI) index. The OHI index is comprised of the combined elevation of soluble CD25 (sCD25) \> 3,900 U/mL and ferritin \>1,000 ng/mL . However, the true incidence and outcomes of HLH/OHI+ in an unselected cohort are unknown, and so is the mechanism of HM-HLH.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Patients with hematologic malignancies * At least 18 years old Exclusion Criteria: * Prior recent treatment (chemotherapy/ other cytoreductive therapies in the last month)

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Meir Medical Center Kfar Saba Israel Recruiting
Rabin Medical Center Petah Tikva Israel Recruiting

More Meir Medical Center trials in Israel

Impact of Blood Cultures Drawn From Arterial Lines on the Incidence of Contamination, Detection of Bacteremia, and Blood Culture Volume Starting soon
Induction ATAD Catheter and Lower Segment Thickness Active, not recruiting
Increased Body Temperature Post Tracheostomy: a Retrospective Study Recruiting
Patients Who Were Not Admitted to the Intensive Care Unit: Characteristics and Clinical Outcomes. Retrospective Study Recruiting
Meir Medical Center Rheumatologic Biobank Recruiting

Other trials for the same condition

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia Recruiting
Assessing DCog Short for Neurotoxicity in CAR-T Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05882175 on ClinicalTrials.gov ↗ ← All trials in Israel